PD-L1 TESTING FOR THE PACIFIC REGIMEN

Testing for PD-L1 at diagnosis is essential regardless of stage1

  • A positive IHC test (TC ≥1%) indicates eligibility for The PACIFIC Regimen*
  • Any validated PD-L1 assay may be used to get a conclusive test result
For patients with PD-L1 ≥1% only (~70% of patients in the PACIFIC study), The PACIFIC Regimen involves treatment with platinum-based CT and RT followed by rapid initiation of IMFINZI.
For patients with PD-L1 ≥1% only (~70% of patients in the PACIFIC study), The PACIFIC Regimen involves treatment with platinum-based CT and RT followed by rapid initiation of IMFINZI.

Patients who initiated IMFINZI within 14 days following CRT had a lower risk of death vs placebo (HR=0.42)2

PRESPECIFIED ANALYSIS OF OS BASED ON TIME TO IMFINZI INITIATION (ITT POPULATION)2

OS favoured IMFINZI in patients with both at least and fewer than 14 days since their last radiation treatment, but it favoured IMFINZI much more strongly in the <14 days group
OS favoured IMFINZI in patients with both at least and fewer than 14 days since their last radiation treatment, but it favoured IMFINZI much more strongly in the <14 days group

Evaluate reflex testing at diagnosis and, following CRT, initiate IMFINZI as soon as the patient is fit enough to receive it

IHC: Immunohistochemistry; CT: Chemotherapy; RT:Radiotherapy; CRT:Chemoradiotherapy

*In PACIFIC, patients were enrolled regardless of their tumour PD-L1 expression level. Patients were retrospectively tested for PD-L1 expression on TC using the Ventana PD-L1 (SP263) IHC assay, where available. 63% of patients provided a tissue sample of sufficient quality and quantity to determine PD-L1 expression and 37% were unknown. OS and PFS with IMFINZI were similar in patients who tested positive for PD-L1 expression and patients in whom PD-L1 status was unknown.1

References: 1.IMFINZI - UK Summary of Product Characteristics. Date: September 2020. 2. Antonia SJ, Villegas A, Daniel D, et al. PACIFIC investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. [published online September 25,2018]. N Engl J Med. 2018;379(24):2342-2350. Supplementary Appendix.